Tatar Erhan, Simsek Cenk, Tasli Funda, Cayhan Veli Kursat, Karatas Murat, Uslu Adam
Department of Nephrology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey.
Exp Clin Transplant. 2017 Feb;15(Suppl 1):265-268. doi: 10.6002/ect.mesot2016.P132.
Rejection is a common cause of late graft dysfunction seen on biopsy studies. The aim of this study was to evaluate indication biopsy findings ? 5 years after kidney transplant and to assess the effectiveness of applied treatments.
Between January 2013 and December 2015, 30 patients who underwent renal transplant indication biopsies and were followed up for ≥ 6 months were evaluated retrospectively. A >30% increase in serum creatinine and/or development of > 1 g/day proteinuria was considered an acceptable indication for biopsy.
Of the 156 indication biopsies obtained within a 3-year period, 30 of them were indication biopsies performed ≥ 5 years after transplant. Twenty patients (67%) demonstrated late graft rejection, 6 patients (20%) had recurrent or de novo glomerulonephritis, and 4 patients (13%) were diagnosed with idiopathic chronic allograft nephropathy. The mean total histologic score was 6.2 ± 2.6, and the chronicity rate was 70%. For patients with late rejection, treatment consisted of pulse steroids in 11, intravenous immunoglobulin in 5, plasmapheresis in 4, antithymocyte globulin in 3, and rituximab in 2 cases. Five patients with glomerulonephritis received pulse steroids, 1 received rituximab therapy, and 3 were treated with cyclophosphamide. The mean follow-up after indication biopsy was 16 ± 11 months. Eleven patients (37%) had a progressive disease course and 7 patients (23%) resumed hemodialysis. Of the 30 patients, the 15 whose glomerular filtration rate was < 30 mL/min/1.72 m² at biopsy were more likely to have a progressive disease course (53% vs. 20%; P = .05) and more commonly resumed dialysis (40% vs. 7%; P = .03).
Rejection was the most common cause of graft dysfunction long term. Chronic histologic changes predominated in indication biopsies ≥ 5 years posttransplant. Regardless of diagnosis, a low glomerular filtration rate at biopsy was closely associated with poor renal outcomes.
移植肾排斥反应是活检研究中晚期移植肾功能障碍的常见原因。本研究旨在评估肾移植术后5年以上的指征性活检结果,并评估所应用治疗方法的有效性。
回顾性评估2013年1月至2015年12月期间接受肾移植指征性活检并随访≥6个月的30例患者。血清肌酐升高>30%和/或蛋白尿>1g/天被认为是活检的可接受指征。
在3年期间获得的156例指征性活检中,30例是移植术后5年以上进行的指征性活检。20例患者(67%)表现为移植肾晚期排斥反应,6例患者(20%)患有复发性或新发肾小球肾炎,4例患者(13%)被诊断为特发性慢性移植肾肾病。平均总组织学评分为6.2±2.6,慢性化率为70%。对于晚期排斥反应患者,11例接受了脉冲类固醇治疗,5例接受了静脉注射免疫球蛋白治疗,4例接受了血浆置换治疗,3例接受了抗胸腺细胞球蛋白治疗,2例接受了利妥昔单抗治疗。5例肾小球肾炎患者接受了脉冲类固醇治疗,1例接受了利妥昔单抗治疗,3例接受了环磷酰胺治疗。指征性活检后的平均随访时间为16±11个月。11例患者(37%)病情呈进展性,7例患者(23%)恢复血液透析。在30例患者中,活检时肾小球滤过率<30mL/min/1.72m²的15例患者更有可能病情呈进展性(53%对20%;P=0.05),且更常恢复透析(40%对7%;P=0.03)。
排斥反应是长期移植肾功能障碍的最常见原因。移植术后5年以上的指征性活检中慢性组织学改变占主导。无论诊断如何,活检时低肾小球滤过率与不良肾脏结局密切相关。